Cadrenal Therapeutics (CVKD) CEO Quang Pham Sells $6.4K of Stock

Executive Sells Shares of CVKD Stock

Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD) recently saw further insider transactions as top leadership trimmed holdings. Quang Pham, who serves as the company's Chairman, Chief Executive Officer, and Interim CFO, parted with 2,127 shares of common stock on June 25, 2026. The disposal was executed at a price of $3.00 per share, bringing the total transaction value to $6,381. Regulatory disclosures confirm this sale was carried out under a pre-planned trading arrangement.

A Series of Recent Insider Sales

This latest transaction follows a frequent pattern of sales by the top executive throughout the month of June. Earlier in the month, Mr. Pham completed multiple disposals of company stock. On June 12, 2026, he sold 12,996 shares for $51,204, and another transaction on the same day covered an identical block of 12,996 shares valued at $51,204. A few days later, on June 15, 2026, he parted with 3,666 shares at an average price of $3.58, totaling $13,124. Activity continued on June 16, 2026, when he sold 3,613 shares at $3.18 each for a total of $11,489. On June 17, 2026, a smaller sale of 513 shares brought in $1,621 at a price of $3.16. Most recently before the June 25 trade, he disposed of 9,029 shares on June 26, 2026, at a price of $3.05 for a total value of $27,538. Several of these transactions were noted as planned moves under specific trading rules.

CVKD Stock Performance and Market Position

Shares of Cadrenal Therapeutics recently traded at a spot price of $3.05. The micro-cap biopharmaceutical company carries a market valuation relative to its small clinical pipeline and early operational stage. The stock has experienced wide swings over the past year, moving between a 52-week low of $1.00 and a 52-week high of $14.64. Technical tracking shows the 50-day moving average sits around $1.72, while the 200-day moving average stands closer to $5.03. Insiders often adjust personal holdings for estate planning, tax reasons, or pre-scheduled diversification, regardless of short-term price movements or moving averages.

Company Focus and Pipeline Developments

Cadrenal Therapeutics is a clinical-stage biopharmaceutical business based in Ponte Vedra, Florida, focusing on novel therapies for immune and thrombotic disorders. Its lead candidate is Tecarfarin, an oral vitamin K antagonist currently being evaluated in Phase 3 clinical trials to prevent dangerous blood clots in patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation. The company is also advancing CAD-1005, a 12-LOX inhibitor designed for heparin-induced thrombocytopenia, alongside Frunexian, a factor XIa inhibitor intended for hospital settings. Investors tracking executive transactions will likely watch for future Form 4 filings and upcoming updates on the company's clinical programs and financial results.